Antitumour potential of BPT: A dual inhibitor of Cdk4 and tubulin polymerization

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Mahale, S ^a   Bharate, S B ^b,c   Manda, S ^b,c   Joshi, P ^b,c   Jenkins, P R ^d   Vishwakarma, R A ^b,c   Chaudhuri, B ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^c ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; FASCAPLYSIN; FLAVOPIRIDOL; N (BIPHENYL 2 YL)TRYPTOLINE; PACLITAXEL; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; CARBOLINE DERIVATIVE; CDK4 PROTEIN, MOUSE; TRYPTOLINE; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG POTENCY; EMBRYO; FIBROBLAST; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL; M PHASE CELL CYCLE CHECKPOINT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; HCT 116 CELL LINE; METABOLISM; MOLECULAR DYNAMICS; POLYMERIZATION; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARBOLINES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MOLECULAR DYNAMICS SIMULATION; POLYMERIZATION; RANDOM ALLOCATION; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947613914     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.96     Document Type: Article

References (53)

1. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25:5220-5227.
2. Yamasaki L. Role of the RB tumor suppressor in cancer. Cancer Treat Res 2003;115:209-239.
3. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
4. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013;19:5320-5328.
5. Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 2001;93:436-446.
6. Lambert AP, Anschau F, Schmitt VM. p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006;80:192-196.
7. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999;18:5311-5317.
8. Sun Y, Luo D, Liao DJ. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinogen 2012;11:12.
9. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-5447.
10. Ikeda Y, Oda K, Kawana K, Aoki D, Osuga Y, Fujii T. Cyclin-dependent kinase 4/6-specific activities as a biomarker for prognosis and chemosensitivity in endometrial cancer. Obstet Gynecol 2014;123:92S.
11. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006;9:13-22.
12. Malumbres M, Barbacid M. Is Cyclin D1-CDK4 kinase a bonafide cancer target? Cancer Cell 2006;9:2-4.
13. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006;9:23-32.
14. Liu N, Fang H, Li Y, Xu W. Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment. Curr Med Chem 2009;16:4869-4888.
15. Tsou H-R, Otteng M, Tran T, Floyd MB, Reich M, Birnberg G et al. 4-(Phenylaminomethylene) isoquinoline-1, 3 (2H, 4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). J Med Chem 2008;51:3507-3525.
16. Cho YS, Angove H, Brain C, Chen CH-T, Cheng H, Cheng R et al. Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors. ACS Med Chem Lett 2012;3:445-449.
17. Tsou H-R, Liu X, Birnberg G, Kaplan J, Otteng M, Tran T et al. Discovery of 4-(benzylaminomethylene) isoquinoline-1, 3-(2H, 4H)-diones and 4-[(pyridylmethyl) aminomethylene]isoquinoline-1, 3-(2H, 4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4. J Med Chem 2009;52:2289-2310.
18. Mascarenhas NM, Ghoshal N. Combined ligand and structure based approaches for narrowing on the essential physicochemical characteristics for CDK4 inhibition. J Chem Inf Model 2008;48:1325-1336.
19. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K et al. Structurebased generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. J Med Chem 2001;44:4615-4627.
20. Aubry C, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD, Sutcliffe MJ. New fascaplysinbased CDK4-specific inhibitors: design, synthesis and biological activity. Chem Commun 2004;15:1696-1697.
21. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified welldifferentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-2028.
22. Mor M, Spadoni G, Diamantini G, Bedini A, Tarzia G, Silva C et al. Antioxidant and cytoprotective activity of indole derivatives related to melatonin. Adv Exp Med Biol 2003;527:567-575.
23. Andreadou I, Tasouli A, Bofilis E, Chrysselis M, Rekka E, Tsantili-Kakoulidou A et al. Antioxidant activity of novel indole derivatives and protection of the myocardial damage in rabbits. Chem Pharm Bull 2002;50:165-168.
24. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014;32:825-837.
25. Joshi KS, Padgaonkar A, Rathos M, Wagh V, Manohar S, Bhatia D et al. Abstract 3054:P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity (Proceedings: AACR 103rd Annual Meeting 2012). Cancer Res 2012;72:3054.
26. Beattie JF, Breault GA, Ellston RP, Green S, Jewsbury PJ, Midgley CJ et al. Cyclindependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4, 6-bis anilino pyrimidines. Bioorg Med Chem Lett 2003;13:2955-2960.
27. Segraves NL, Robinson SJ, Garcia D, Said SA, Fu X, Schmitz FJ et al. Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. J Nat Prod 2004;67:783-792.
28. Hormann A, Chaudhuri B, Fretz H. DNA binding properties of the marine sponge pigment fascaplysin. Bioorg Med Chem 2001;9:917-921.
29. Mahale S, Bharate SB, Manda S, Joshi P, Bharate SS, Jenkins PR et al. Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a non-planar analog of fascaplysin inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity. J Med Chem 2014;57:9658-9672.
30. Aubry C, Wilson AJ, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD et al. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin. Org Biomol Chem 2006;4:787-801.
31. Mahale S, Aubry C, James Wilson A, Jenkins PR, Marechal JD, Sutcliffe MJ et al. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorg Med Chem Lett 2006;16:4272-4278.
32. Mahale S, Aubry C, Jenkins PR, Marechal JD, Sutcliffe MJ, Chaudhuri B. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorg Chem 2006;34:287-297.
33. Day PJ, Cleasby A, Tickle IJ, O'Reilly M, Coyle JE, Holding FP, et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA 2009;106:4166-4170.
34. Yonekura N, Mutoh M, Miyagi Y E T. Ethidium bromide binding sites in DNA gel. Chem Lett 2000;8:954-958.
35. Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 2015;1853:89-100.
36. Augustin E, Wheatley DN, Lamb J, Konopa J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol 1996;38:39-44.
37. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995;92:8493-8497.
38. Blagosklonny MV. Cell senescence and hypermitogenic arrest. EMBO Rep 2003;4:358-362.
39. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999;96:4325-4329.
40. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-465.
41. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L et al. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006;42:422-446.
42. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-9086.
43. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
44. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by antimicrotubule agents in human lung cancers. Am J Pathol 2003;163:1109-1116.
45. Aubry C, Patel A, Mahale S, Chaudhuri B, Maréchal J-D, Sutcliffe MJ et al. The design and synthesis of novel 3-[2-indol-1-yl-ethyl]-1H-indole derivatives as selective inhibitors of CDK4. Tetrahedron Lett 2005;46:1423-1425.
46. Lee JC, Timasheff SN. In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 1977;16:1754-1764.
47. Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S. Inhibition of Akt and MAPK pathways elevated potential of TNFalpha in inducing apoptosis in ameloblastoma. Oral Oncol 2006;42:39-45.
48. Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST et al. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998;16:19-25.
49. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K et al. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996;10:130-137.
50. Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 1989;24:187-192.
51. Shafiq MI, Steinbrecher T, Schmid R. Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. PLoS One 2012;7:e42612.
52. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-320.
53. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.